DHEA Augmentation of Musculoskeletal Adaptations to Exercise in Older Women

Osteoporosis, Postmenopausal Clinical Trial

Official title:

DHEA Augmentation of Musculoskeletal Adaptations to Exercise in Older Women

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03227458
• Other study ID #: 16-2427
• Secondary ID: R01AG053489
• Status: Active, not recruiting
• Phase: N/A
• Start date: February 12, 2018
• Est. completion date: June 2024

Study information

• Verified date: May 2024
• Source: University of Colorado, Denver
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To determine whether the musculoskeletal adaptations to bone-loading exercise can be significantly augmented in older women (aged 60-85) with low bone mass (osteopenia; T-scores <-1.0 and >-2.5) or moderate osteoporosis (T-scores < -2.5 and >= -3.0) and by restoring serum DHEAS to young adult levels by oral DHEA replacement.

Description:

This will be the first study to measure changes in areal bone mineral density (aBMD) and fat-free mass (FFM) in response to dehydroepiandrosterone (DHEA) alone and combined with exercise in postmenopausal women. The body of evidence from carefully executed Randomized Controlled Studies (RCTs) provides support for DHEA therapy to increase aBMD and FFM in older women. Less is known about whether DHEA therapy enhances the effects of exercise on the aging musculoskeletal system when an appropriate mechanical stimulus is applied.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 152
• Est. completion date: June 2024
• Est. primary completion date: June 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 55 Years to 85 Years

Eligibility

Inclusion Criteria:

• non-frail, as determined by short physical performance battery (SPPB) score > 9 (0-12 scale);

• 5 years or longer since menopause (defined as last menstrual period);

• willing to participate in a 36-week exercise program that will start at a moderate intensity and gradually progress to a higher intensity;

• willing to be randomized to an exercise or a no-exercise arm of the study;

• willing to take DHEA (50mg/d) or a placebo pill daily and remain blinded for up to 36 weeks;

• not performing resistance exercise training or high impact weight-bearing exercise (e.g., jogging) = 2 days per week in the past 6 months;

• ambulatory without assistive devices;

• serum DHEAS < 140 µg/dL (3.8 µmol/L);

• low bone mass or moderate osteoporosis defined as lumbar spine or proximal hip aBMD t-scores < -1.0 and > = -3.0;

• refusal of standard osteoporosis treatment in women with moderate osteoporosis (BMD t-scores >=-3.0 and =< 2.5).

• evidence of a negative (no findings suspicious for breast cancer) mammogram within the past 12 months;

• planning to reside in the Denver area for the duration of the study

• normal cognitive function, as determined by a Mini-Cog score > = 4

Exclusion Criteria:

• history of hospitalization for Corona Virus Disease-19 (COVID-19)

• does not meet Centers for Disease Control and Prevention (CDC) recommendations for home isolation because has had a positive severe acute respiratory syndrome corona virus-2 (SARS-COV-2) test less than 10 days before study entry; or has had fever within the past 3 days and respiratory symptoms have not improved; or symptoms first appeared less than 10 days before study entry

• uncontrolled hypertension defined as resting systolic blood pressure (sBP) >150 mmHg or diastolic blood pressure (dBP) >90 mmHg; participants who do not meet these criteria at first screening will be re-evaluated, including follow-up evaluation by their Primary Care Physician (PCP) with initiation or adjustment of anti-hypertensive medications;

• diagnosed ischemic heart disease or indicators of unstable ischemic heart disease (e.g., angina, ST segment depression) or arrhythmias at rest or during the Gated Exercise Test (GXT) without negative follow-up evaluation will be cause for exclusion; follow-up evaluation must include diagnostic testing (e.g., thallium stress test) with interpretation by a cardiologist;

• diagnosis of heart failure, clinically significant aortic stenosis, uncontrolled angina, or uncontrolled arrhythmia.

• pulmonary disease requiring use of oral steroids within the previous 6 months or the use of supplemental oxygen = 4 liters with physical exertion

• orthopedic problems (e.g., severe osteoarthritis, rheumatoid arthritis) that greatly limit the ability to perform moderate to high intensity resistance exercise (e.g., unable to be properly positioned in exercise equipment or to have severely restricted range of motion even after modifications have been made)

• hip fracture, hip or knee replacement, or spinal surgery in the past 6 months;

• undergoing physical therapy involving the lower extremities;

• hematocrit (HCT) > 54%;

• thyroid dysfunction, defined as an ultrasensitive thyroid stimulating hormone (TSH) < 0.4 or > 10.0 microunits/mL;, without signs or symptoms of clinical hypo- or hyperthyroidism. Volunteers with abnormal TSH values will be re-considered for participation in the study after follow-up evaluation by their PCP with initiation or adjustment of thyroid hormone replacement;

• acute liver disease indicated by liver function tests (alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase) = 1.5 times the upper limits of normal;

• estimated glomerular filtration rate (eGFR) < 45, using the Modification of Diet in Renal Disease (MDRD) equation (Levey et al, Annals Inter Med, 1999; Munter et al, Clin J Am Soc Nephrology, 2009);

• poorly controlled diabetes mellitus based on HbA1c > 8.5%, or use of insulin;

• fasted serum triglycerides > 400 mg/dL;

• serum 25-hydroxy vitamin D <20 ng/mL; volunteers will be re-considered for participation in the study after follow-up evaluation by their PCP with initiation or adjustment of vitamin D supplementation per the study's vitamin D repletion protocol.

• use of DHEA supplementation or sex hormones in the past 6 months. Use of prescription low dose vaginal estrogen creams (Premarin or Estrace) 3 days per week will not be exclusionary.

• use in the past 6 months of any medications known to alter bone metabolism (e.g., oral glucocorticoids, bone anti-resorptive agents);

• documented history of cognitive impairment or dementia, or Mini-Cog < 4;

• current smoker;

• personal history of breast, ovarian, metastatic endometrial, or cervical cancer;

• any cancer requiring treatment in the past 3 years except non-melanoma skin cancers;

• un-diagnosed vaginal bleeding;

• women who, in the judgment of the study physician, appear incapable of safely participating in the exercise (e.g., neuromuscular/musculoskeletal impairment)

• use of insulin;

• lumbar spine, total hip, or femoral neck aBMD t-scores < -3.0;

• secondary osteoporosis

Related Conditions & MeSH terms

• Low Bone Mass
• Osteoporosis
• Osteoporosis, Postmenopausal

Intervention

Other:
• DHEA
Participants will take 1 study pill (50 mg DHEA) daily for 36 weeks.
• Placebo
Participants will take placebo daily for 36 weeks.

Behavioral:
• Exercise
bone-loading exercise on 3 days per week for 38 weeks

Locations

Country	Name	City	State
United States	University of Colorado Anschutz Medical Campus	Aurora	Colorado

Sponsors (2)

Lead Sponsor	Collaborator
University of Colorado, Denver	National Institute on Aging (NIA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in lumbar spine aBMD	mean change from baseline in lumbar spine aBMD	Baseline and 36 Weeks
Secondary	Change in total hip aBMD	mean change from baseline in total hip aBMD	36 Weeks
Secondary	Change in regional hip aBMD	mean change from baseline in regional hip aBMD	Baseline and 36 Weeks
Secondary	Change in Vertebral (L1-2) total volumetric bone mineral density (vBMD)	mean change from baseline in vertebral total volumetric BMD	Baseline and 36 Weeks
Secondary	Change in Vertebral (L1-2) cortical vBMD	mean change from baseline in vertebral cortical volumetric BMD	Baseline and 36 Weeks
Secondary	Change in Vertebral (L1-2) trabecular vBMD	mean change from baseline in vertebral trabecular volumetric BMD	Baseline and 36 Weeks
Secondary	Change in Femoral total vBMD	mean change from baseline in femoral total volumetric BMD	Baseline and 36 Weeks
Secondary	Change in Femoral cortical vBMD	mean change from baseline in femoral cortical volumetric BMD	Baseline and 36 Weeks
Secondary	Change in Femoral trabecular vBMD	mean change from baseline in femoral trabecular volumetric BMD	Baseline and 36 Weeks
Secondary	Change in Vertebral (L1-2) strength, stance model	mean change from baseline in the estimated strength of L1-2 vertebrae in a stance model	Baseline and 36 Weeks
Secondary	Change in Vertebral (L1-2) strength, fall model	mean change from baseline in the estimated strength of L1-2 vertebrae in a fall model	Baseline and 36 Weeks
Secondary	Change in Proximal femur strength, stance model	mean change from baseline in the estimated strength of the proximal femur in a stance model	Baseline and 36 Weeks
Secondary	Change in Proximal femur strength, fall model	mean change from baseline in the estimated strength of the proximal femur in a fall model	Baseline and 36 Weeks
Secondary	Change in Total body fat-free mass	mean change from baseline in total body fat-free mass	Baseline and 36 Weeks